Table 2 Treatment and outcome of 10 primary lacrimal sac lymphomas in a predominantly white population.

Case	Diagnosis	Treatment		Ann Arbor stage of disease (diagnosis → follow up → last follow up)		Follow up period (years)	Alive/dead (years after diagnosis)
A	DLBCL	Palliative RT		Not investigated because of old age		None	DOD (1)
B	DLBCL	Surgery + CHOP × 3 + RT 30 Gy		I → NA		NA	NA
E	DLBCL	CHOP × 4 + RT 40 Gy		I → CR		5	Alive (5)
F	MALT	Incomplete excision. Refused further treatment		I → I		1	Alive (1)
G	MALT	Surgery + RT regional and other LN, 40 Gy + CHOP × 6		I → IV		7	Dead, cause unknown (10)
J	MALT	RT 45 Gy		I → CR		12	Alive (12)
K	Transitional MALT	Rituximab dose NA		I → II → CR		2	NA
L	Transitional MALT	Surgery + CHOP × 3		II* → IV		3	DOD (3)
N	B cell, unclassified	RT dose NA		I → NA		NA	NA
O	B cell, unclassified	CHOP × 3 + RT 40 Gy		I → CR		NA	NA

CHOP, cyclophosphamide + hydroxydoxorubicine + oncovine + prednisone; CR, complete remission; DLBCL, diffuse large B cell lymphoma; DOD, dead of disease; Gy, Gray; LN, lymph nodes; MALT, extranodal marginal zone B cell lymphoma of mucosa associated lymphoid tissue; NA, not available; RT, radiation therapy.

*This patient had symptoms from the lacrimal sac more than 6 months before diagnosis was made.